Given the efficacy and safety of an anti-TSLP monoclonal antibody, tezepelumab, in a phase 3 clinical trial of severe asthma [13] and a phase 2a clinical trial of atopic dermatitis [55], anti-TSLP therapy might also be a potential treatment for the development of neuropathic pain in adults. This evidence concerns the gene TSLP and atopic eczema.